[
  {
    "ts": null,
    "headline": "Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?",
    "summary": "BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.",
    "url": "https://finnhub.io/api/news?id=201eee4a76dd71d58f6c2edd6ba072051a30d268602353be94fef49990373258",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770136740,
      "headline": "Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?",
      "id": 138345548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.",
      "url": "https://finnhub.io/api/news?id=201eee4a76dd71d58f6c2edd6ba072051a30d268602353be94fef49990373258"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Messy Q4 Earnings Mask An Improving Business",
    "summary": "Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.",
    "url": "https://finnhub.io/api/news?id=d35b5f6efcdfd74537a4380fb1cdfc64300a2eb6f057c7f117ef2a0e25c3daf3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770127379,
      "headline": "Pfizer: Messy Q4 Earnings Mask An Improving Business",
      "id": 138345061,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1372778958/image_1372778958.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.",
      "url": "https://finnhub.io/api/news?id=d35b5f6efcdfd74537a4380fb1cdfc64300a2eb6f057c7f117ef2a0e25c3daf3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
    "summary": "PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
    "url": "https://finnhub.io/api/news?id=1fab5cfafb6210e5e1cf4b0b6623877b065cc36e8c5967b2d79a54c6c3eb0683",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770119940,
      "headline": "Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
      "id": 138341606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., February 03, 2026--Bristol Myers Squibb Introduces \"Change the Target. Change What’s Possible.\" to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care",
      "url": "https://finnhub.io/api/news?id=1fab5cfafb6210e5e1cf4b0b6623877b065cc36e8c5967b2d79a54c6c3eb0683"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY) Poised for Upside With Registrational Data Ahead",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 on January 13, maintaining an Outperform rating on the company’s shares. The firm cited substantial pipeline flexibility in 2026 as the key justification for the higher […]",
    "url": "https://finnhub.io/api/news?id=7167455c6ce17fb8d7ded8be79b32732fe900098752199cc607c32800819d7d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770113527,
      "headline": "Bristol-Myers Squibb (BMY) Poised for Upside With Registrational Data Ahead",
      "id": 138340807,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 on January 13, maintaining an Outperform rating on the company’s shares. The firm cited substantial pipeline flexibility in 2026 as the key justification for the higher […]",
      "url": "https://finnhub.io/api/news?id=7167455c6ce17fb8d7ded8be79b32732fe900098752199cc607c32800819d7d3"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Bristol-Myers Squibb Company on Disruptive Analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company’s share was trading at $55.05 as of January 30th. BMY’s trailing and forward P/E were 18.28 and 9.09, respectively according to Yahoo Finance. Bristol-Myers Squibb Company discovers, develops, […]",
    "url": "https://finnhub.io/api/news?id=9b9dde0e495999569519704001c0f19f51ca2787a1558d63fae823ee7b1bbdc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770078539,
      "headline": "Bristol-Myers Squibb Company (BMY): A Bull Case Theory",
      "id": 138338044,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Bristol-Myers Squibb Company on Disruptive Analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company’s share was trading at $55.05 as of January 30th. BMY’s trailing and forward P/E were 18.28 and 9.09, respectively according to Yahoo Finance. Bristol-Myers Squibb Company discovers, develops, […]",
      "url": "https://finnhub.io/api/news?id=9b9dde0e495999569519704001c0f19f51ca2787a1558d63fae823ee7b1bbdc9"
    }
  }
]